Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common stock has been listed on The Nasdaq Global Select Market under the symbol “ATRA” since October 16, 2014. Prior to that time, there was no public market for our common stock.
On February 18, 2021, there were 6 stockholders of record of our common stock. We are unable to estimate the total number of stockholders represented by these record holders, as many of our shares are held by brokers and other institutions on behalf of our stockholders.
Dividend Policy
We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings for use in the operation of our business and do not intend to declare or pay any cash dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant.
Securities Authorized for Issuance under Equity Compensation Plans
Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.
68
Stock Performance Graph
The following graph compares the cumulative total return on an indexed basis of a $100 investment, made at the beginning of the five-year period ended December 31, 2020, in the Company’s common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index.
This performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing of Atara Biotherapeutics, Inc. under the Securities Act or the Exchange Act, except to the extent we specifically incorporate it by reference into such filing. The past performance of our common stock is not an indication of future performance.
COMPARISON OF FIVE-YEAR CUMULATIVE TOTAL RETURN
As of December 31,
Atara Biotherapeutics, Inc.
Nasdaq Composite
Nasdaq Biotechnology
2015
$
100.00
$
100.00
$
100.00
2016
53.77
107.50
78.32
2017
68.53
137.86
94.81
2018
131.54
132.51
85.97
2019
62.36
179.19
106.95
2020
74.33
257.38
134.42
69
Item 6. Selected Financial Data
The following selected consolidated financial data of the Company for each of the periods indicated are derived from the Company’s audited consolidated financial statements. The consolidated financial statements of the Company as of December 31, 2020 and 2019 and for the years ended December 31, 2020 , 2019 and 2018 , and the related reports of the independent registered public accounting firm are included elsewhere in this Annual Report on Form 10-K. The data presented below should be read in conjunction with the Company’s financial statements, the notes thereto, and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this report.
Consolidated Statements of Operations and
Year ended December 31,
Comprehensive Loss Data:
2020
2019
2018
2017
2016
(In thousands, except per share amounts)
Operating expenses:
Research and development
$
244,650
$
216,097
$
167,457
$
81,206
$
56,514
General and administrative
64,402
79,584
69,654
40,326
24,728
Total operating expenses
309,052
295,681
237,111
121,532
81,242
Loss from operations
(309,052
)
(295,681
)
(237,111
)
(121,532
)
(81,242
)
Interest and other income, net
2,447
4,717
6,368
2,027
2,203
Loss before provision for income taxes
(306,605
)
(290,964
)
(230,743
)
(119,505
)
(79,039
)
Provision for (benefit from) income taxes
15
12
(44
)
(14
)
10
Net loss
$
(306,620
)
$
(290,976
)
$
(230,699
)
$
(119,491
)
$
(79,049
)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities
76
560
(189
)
32
335
Comprehensive loss
$
(306,544
)
$
(290,416
)
$
(230,888
)
$
(119,459
)
$
(78,714
)
Basic and diluted net loss per common share
$
(4.15
)
$
(5.67
)
$
(5.27
)
$
(4.00
)
$
(2.75
)
As of December 31,
Consolidated Balance Sheet Data:
2020
2019
2018
2017
2016
(In thousands)
Cash, cash equivalents and short-term investments
$
500,659
$
259,109
$
309,631
$
166,096
$
255,682
Working capital
$
440,372
$
236,249
$
281,510
$
144,544
$
250,878
Total assets
$
588,120
$
342,942
$
391,839
$
217,779
$
263,914
Long-term liabilities
$
42,880
$
15,418
$
13,003
$
12,269
$
503
Total stockholders' equity
$
462,339
$
290,781
$
338,857
$
177,864
$
253,736
70